Effects of kappa agonists and dexoxadrol on the acquisition of conditional discriminations in monkeys.
In each of two components of a multiple schedule, patas monkeys were required to respond on a right or left lever depending upon the stimulus combination (a color and a geometric form) presented. Reinforcement of a response in the presence of one stimulus (the form) was conditional upon the other stimulus (the color). The completion of a two-member chain of discriminations produced a food pellet. Errors produced a brief timeout. One component of the multiple schedule was a repeated-acquisition task in which the discriminative stimuli for left- and right-lever responses changed each session (learning). In the other component, the discriminative stimuli were the same each session (performance). Dose-effect curves were determined for the kappa agonists bremazocine, tifluadom, ethylketocyclazocine and U50488H. Each drug produced dose-related decreases in overall response rate but had little or no effect on accuracy in either learning or performance. The rate-decreasing effects of ethylketocyclazocine and tifluadom were due to a dose-related pause at the start of the session, whereas those of bremazocine and U50488 were due largely to sporadic pausing throughout the session. Naltrexone blocked the effects of each drug whereas quaternary naltrexone had no effect. In contrast to the kappa agonists, dexoxadrol produced a dose-related disruption in accuracy of responding in learning. Dexoxadrol also decreased response rate in both acquisition and performance in a dose-related manner. Naltrexone attenuated the effects of low doses of dexoxadrol on accuracy, but failed to block the disruptive effects of higher doses.(ABSTRACT TRUNCATED AT 250 WORDS)
Moerschbaecher
J M
JM
Department of Pharmacology and Experimental Therapeutics, Louisiana State University Medical Center, New Orleans.
Brocklehurst
C
C
Devia
C
C
Faust
W B
WB
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001575:Benzomorphans / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects*; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004148:Dioxolanes / Q000494:pharmacology*; D004149:Dioxoles / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004901:Erythrocebus patas; D016314:Ethylketocyclazocine; D005260:Female; D008252:Macaca fascicularis; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D011957:Receptors, Opioid / Q000187:drug effects*; D017473:Receptors, Opioid, kappa
D000700:Analgesics; D001575:Benzomorphans; D004148:Dioxolanes; D004149:Dioxoles; D010880:Piperidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; C005840:dioxadrol; D016314:Ethylketocyclazocine; D009271:Naltrexone; C027248:bremazocine; D003496:Cyclazocine; C579650:dexoxadrol